Mucosal Melanoma — Variants & evidence

Mucosal Melanoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

5 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–5 of 5 evidence items (1 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ALK Alternative Transcript (ATI)1
Entrectinib	Mucosal Melanoma	Predictive	C	Does Not Support Sensitivity Response	4	accepted	EID7421 ALK expression was analyzed in 45 melanoma patient-derived xenografts (PDXs), with 11/45 showing ALK expression. Four PDX tumours had only wild-type ALK expression, four had only ALK alternative trans… (full text at CIViC) PMID 29054983 · Couts et al., 2018 · Open in CIViC	civic
KIT Amplification1
Imatinib	Mucosal Melanoma	Predictive	B	Supports Resistance	3	accepted	EID1466 Phase 2 trial in metastatic mucosal, acral or chronically sun-damaged melanoma. Twenty-five patients were enrolled (24 evaluable). Eight patients (33%) had tumors with KIT mutations, 11 (46%) with KIT… (full text at CIViC) PMID 23775962 · Hodi et al., 2013 · Open in CIViC	civic
KIT Internal Duplication1
Imatinib	Anal MelanomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID302 In a case study, a patient with anal melanoma harboring a 7 codon duplication in the juxtamambrane region (exon 11) of KIT showed marked response 4 months after imatinib treatment. PMID 18421059 · Hodi et al., 2008 · Open in CIViC	civic
KIT K642E1
Imatinib	Mucosal Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID2889 A 69 y.o. woman presented with metastatic mucosal melanoma of the anus. KIT was amplified in the tumor and harbored the K642E mutation. Post surgery with extensive margins, she was given a dose of ant… (full text at CIViC) PMID 18510589 · Lutzky et al., 2008 · Open in CIViC	civic
NRAS Q61L1
Belvarafenib	Mucosal Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID13215 A patient with mucosal melanoma harboring NRAS Q61L received belvarafenib monotherapy after five prior lines of systemic therapy and achieved a confirmed partial response by RECIST. The patient receiv… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic

Data updated 7 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.